What are the recommended colchicine dosing regimens for acute gout flares and prophylaxis in adults, and how should the dose be adjusted for renal or hepatic impairment and in elderly patients?

Colchicine Dosing for Gout

Acute Gout Flare Treatment

For acute gout flares, administer 1.2 mg (two tablets) at the first sign of flare followed by 0.6 mg (one tablet) one hour later, for a total maximum dose of 1.8 mg over one hour. 1, 2

• This FDA-approved low-dose regimen is equally effective as higher doses but avoids severe gastrointestinal toxicity. 3, 4
• Treatment should be initiated within 36 hours of symptom onset for optimal efficacy. 3
• Higher doses have not been found to be more effective and should be avoided. 2
• Continue therapy at the prescribed dose until the flare completely resolves, typically within 7–14 days. 3

Critical Timing Consideration

• If a patient is already taking colchicine prophylaxis and experiences a flare, administer the acute treatment dose (1.2 mg followed by 0.6 mg one hour later), then wait 12 hours before resuming the prophylactic dose. 2

---

Prophylaxis of Gout Flares

For prophylaxis, prescribe 0.6 mg once or twice daily, with a maximum dose of 1.2 mg/day. 1, 2

• Prophylaxis is strongly recommended when initiating urate-lowering therapy (allopurinol, febuxostat, pegloticase) due to mobilization of urate from tissue deposits. 2
• Continue prophylaxis for at least 6 months after starting urate-lowering therapy. 1, 2
• Recent evidence shows 0.5 mg once daily is non-inferior to twice-daily dosing for flare prevention, with better tolerability and lower cost. 5

---

Renal Impairment Dose Adjustments

Prophylaxis Dosing in Renal Impairment

Mild impairment (CrCl 50–80 mL/min):

• No dose adjustment required; monitor closely for adverse effects. 2

Moderate impairment (CrCl 30–50 mL/min):

• No dose adjustment required, but close monitoring is essential. 2
• Consider 0.48 mg daily (using oral solution) or 0.5 mg tablet for optimal therapeutic levels. 6

Severe impairment (CrCl 15–29 mL/min):

• Start at 0.3 mg/day; increase cautiously with close monitoring. 2
• Standard 0.6 mg daily dose results in plasma levels exceeding maximum tolerated levels 36% of the time. 6

Dialysis patients:

• Start at 0.3 mg twice weekly with close monitoring. 2

Acute Flare Treatment in Renal Impairment

Mild to moderate impairment (CrCl 30–80 mL/min):

• No dose adjustment needed, but monitor closely. 2

Severe impairment (CrCl 15–29 mL/min):

• Use standard acute dose (1.2 mg + 0.6 mg), but repeat no more than once every 2 weeks. 2
• Consider alternative therapy for patients requiring repeated courses. 2

Dialysis patients:

• Reduce to single 0.6 mg dose; repeat no more than once every 2 weeks. 2

Critical Renal Function Threshold

• Estimated creatinine clearance ≤50 mL/min is the most practical predictor of colchicine toxicity risk with chronic use. 7
• Colchicine should not be prescribed to patients with severe renal insufficiency or combined hepatic-renal insufficiency. 8

---

Hepatic Impairment

Patients with hepatic impairment require careful dose reduction and monitoring, though specific FDA guidance defers to clinical judgment. 2

• Combined hepatic-renal insufficiency is an absolute contraindication to colchicine. 8
• When hepatic impairment coexists with any degree of renal dysfunction, colchicine should be avoided entirely. 2

---

Drug Interaction Dose Adjustments

Strong CYP3A4 Inhibitors (e.g., clarithromycin, ketoconazole, ritonavir)

Prophylaxis:

• Reduce from 0.6 mg twice daily to 0.3 mg once daily. 2
• Reduce from 0.6 mg once daily to 0.3 mg every other day. 2

Acute flare treatment:

• Reduce from standard dose to 0.6 mg × 1 dose, followed by 0.3 mg one hour later. 2
• Repeat no earlier than 3 days. 2

Critical contraindication: Patients with renal or hepatic impairment should NOT receive colchicine with strong CYP3A4 inhibitors. 2

Moderate CYP3A4 Inhibitors (e.g., diltiazem, verapamil, erythromycin)

Prophylaxis:

• Reduce from 0.6 mg twice daily to 0.3 mg twice daily or 0.6 mg once daily. 2
• Reduce from 0.6 mg once daily to 0.3 mg once daily. 2

Acute flare treatment:

• Reduce from standard dose to 1.2 mg × 1 dose (no second dose). 2
• Repeat no earlier than 3 days. 2

P-glycoprotein Inhibitors (e.g., cyclosporine, ranolazine)

Fatal colchicine toxicity has been reported with cyclosporine. 2

• Use the same dose reductions as for strong CYP3A4 inhibitors. 2
• Patients with renal or hepatic impairment should NOT receive colchicine with P-gp inhibitors. 2

---

Elderly Patients

Elderly patients require dose adjustment based on estimated creatinine clearance using the Cockcroft-Gault equation, which accounts for age. 2

• Age is a critical factor in the clearance calculation: CrCl = [140 - age (years) × weight (kg)] / [72 × serum creatinine (mg/dL)] × 0.85 for females. 2
• Many elderly patients will have reduced clearance requiring dose reduction even with "normal" serum creatinine due to age-related decline in renal function. 2
• Elderly patients are at higher risk for myotoxicity with chronic colchicine use, particularly when creatinine clearance is ≤50 mL/min. 7

---

Common Pitfalls to Avoid

Never use high-dose colchicine regimens (e.g., 0.6 mg every hour for multiple doses), as they cause severe gastrointestinal toxicity without added efficacy. 3

Do not split or alternate-day dose standard tablets in moderate renal impairment (0.3 mg daily or 0.6 mg every other day), as this results in subtherapeutic levels 20–70% of the time. 6

Always check for drug interactions before prescribing colchicine, as fatal toxicity has been reported with CYP3A4 and P-gp inhibitors. 2

Do not prescribe colchicine for acute flare treatment to patients already on prophylaxis who are taking strong CYP3A4 inhibitors. 2

Avoid NSAIDs as alternatives in patients with chronic kidney disease, heart failure, cirrhosis, or prior GI bleeding—use corticosteroids instead. 3